Clinical Trials on ER Breast Cancer

Total 53945 results

Memorial Sloan Kettering Cancer Center
Context Therapeutics Inc.

Withdrawn

A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer

Metastatic Breast Cancer | Unresectable Breast Cancer

United States
Ohio State University Comprehensive Cancer Center

Active, not recruiting

Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer (IMPACT)

Depression | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Cognitive Side Effects of Cancer Therapy

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer

HER2-positive Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer

Stage IV Breast Cancer | Stage IIIB Breast Cancer | Recurrent Breast Cancer

United States
National Cancer Institute (NCI)

Terminated

Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer

HER2-positive Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer

Advanced Breast Cancer | Metastatic Breast Cancer

China
Washington University School of Medicine
Biovica

Not yet recruiting

BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer

Metastatic Breast Cancer | Unresectable Breast Cancer

United States
Ahon Pharmaceutical Co., Ltd.

Recruiting

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Advanced Breast Cancer | Female Breast Cancer

China
Ahon Pharmaceutical Co., Ltd.

Recruiting

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Advanced Breast Cancer | Female Breast Cancer

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Advanced Breast Cancer | Metastatic Breast Cancer

China
Stanford University
National Institutes of Health (NIH)

Recruiting

Magnetic Resonance Imaging of Breast Cancer

Breast Cancer | Breast Cancer Non-invasive Breast Cancer

United States
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.

Advanced Breast Cancer | Metastatic Breast Cancer

China
Onco Medical Consult GmbH
Eli Lilly and Company; Institut fuer Frauengesundheit

Unknown

Implementing Patients´ Competence in Oral Breast Cancer Therapy (IMPACT)

Advanced Breast Cancer | Metastatic Breast Cancer
AstraZeneca

Completed

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg (FINDER II)

Advanced Breast Cancer | Metastatic Breast Cancer

Belgium, Turkey, Canada, Poland, Romania, Hungary, France, Czechia
University of California, Irvine

Completed

Overall Diet Quality and Breast Cancer Risk

Invasive Breast Cancer | Incident Breast Cancer
Chang Gung Memorial Hospital
Eisai Co., Ltd.; Kaohsiung Breast Cancer Prevention and Education Society (KBCPES)

Unknown

Halaven Patient Registry (Metastatic Breast Cancer, MBC)

Advanced Breast Cancer | Metastatic Breast Cancer

Taiwan
Neovii Biotech

Terminated

Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment

Advanced Breast Cancer | Metastatic Breast Cancer

Spain, Austria, France, Germany, Italy
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer

Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Ductal Breast Carcinoma in Situ | Lobular Breast Carcinoma in Situ

United States
Hebei Medical University Fourth Hospital

Recruiting

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

Advanced Breast Cancer | HER2-positive Breast Cancer

China
Spanish Breast Cancer Research Group
AstraZeneca

Recruiting

Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab (TRANSCENDER)

Metastatic Breast Cancer | Locally Advanced Breast Cancer

Spain
Institut fuer Frauengesundheit
Samsung Bioepis Co., Ltd.

Recruiting

Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON) (NeoON)

Breast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Female

Germany
Saint Luke's Health System
Novartis Pharmaceuticals

Recruiting

Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer

Metastatic Breast Cancer | HER2-negative Breast Cancer

United States
Wake Forest University Health Sciences
Atrium Health Navicent

Active, not recruiting

IORT-Breast at Medical Center Navicent Health (IORT-Breast)

Breast Cancer Female | Early-stage Breast Cancer

United States
GlycoMimetics Incorporated

Terminated

A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer

Breast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast Cancer

United States
Shandong Cancer Hospital and Institute

Unknown

Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC

Metastatic Breast Cancer | HER2-positive Breast Cancer
Meabco A/S

Completed

BP-C1 in Metastatic Breast Cancer Patients

Metastatic Breast Cancer | Stage IV Breast Cancer

Israel, Thailand
Meabco A/S
Meddoc; Norwegian University of Life Sciences

Completed

BP-C1 in Short-term Treatment of Thai Patients With Metastatic Breast Cancer

Metastatic Breast Cancer | Stage IV Breast Cancer

Thailand
Imperial College London
Cancer Research UK

Completed

A Study of the Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastatic Breast Cancer. (IRIS)

Metastatic Breast Cancer | Locally Advanced Breast Cancer

United Kingdom
National Cancer Institute (NCI)

Completed

Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Recurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States
Jonsson Comprehensive Cancer Center

Completed

Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis

HER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer | Central Nervous System Metastases

United States
Dana-Farber Cancer Institute
Genentech, Inc.

Active, not recruiting

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Breast Cancer | Stage II Breast Cancer | HER-2 Positive Breast Cancer | Stage III Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer

United States
National Cancer Institute (NCI)

Terminated

Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer

Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Advanced Breast Carcinoma | Metastatic Breast Carcinoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Genentech, Inc.

Terminated

GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer

Triple Negative Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Estrogen Receptor Negative Breast Cancer

United States
European Institute of Oncology

Recruiting

fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases (fREEDOM)

Triple Negative Breast Cancer | HER2-positive Breast Cancer | Invasive Breast Cancer

Italy
Akeso

Recruiting

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

Metastatic Triple-negative Breast Cancer | Locally Advanced Triple-negative Breast Cancer

China
Jonsson Comprehensive Cancer Center
Faxitron bioptics, LLC

Completed

SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer

Stage I Breast Cancer AJCC v7 | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Recurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Early Stage Triple-Negative Breast Carcinoma

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Male Breast Carcinoma | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States, Puerto Rico
University of Michigan Rogel Cancer Center
National Cancer Institute (NCI)

Completed

The ConnectedCancerCare Pilot Study (CCC) (CCC)

Breast Cancer Female | Survivorship | Early-stage Breast Cancer | Cancer Survivors | Transitional Care

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Gateway for Cancer Research

Active, not recruiting

Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment

Stage I Breast Cancer AJCC v7 | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB... and other conditions

United States
Wake Forest University Health Sciences
Merck Sharp & Dohme LLC

Completed

Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer (PePPy)

Male Breast Cancer | Breast - Female

United States
University of Pennsylvania

Active, not recruiting

[18F]FES PET/CT in Endocrine Refractory Breast Cancer

Breast Neoplasm | Metastatic Breast Cancer | Estrogen Receptor Positive Breast Cancer

United States
Medical College of Wisconsin

Recruiting

Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer

Invasive Breast Cancer

United States
Organon and Co
Institute for Applied Economics and Health Research Aps

Completed

Finasteride (MK-0906) and Male Breast Cancer - A Register-Based Nested Case-Control Study (MK-0906-162/2003.021).

Male Breast Cancer
Dompé Farmaceutici S.p.A
PRA Health Sciences

Completed

A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer (FRIDA)

Metastatic Breast Cancer

United States, Spain, Belgium, Italy, France, Czechia, Poland
German Breast Group
Pfizer

Completed

Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients (MALE)

Male Breast Cancer

Germany
Salah Azaïz Cancer Institute

Unknown

Understanding Male Breast Cancer: Salah Azaïz Cancer Institute Experience

Male Breast Cancer

Tunisia

Clinical Trials on ER Breast Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations